European Primary Care Cardiovascular Society

What are potential mechanisms of benefit of icosapent ethyl?

10' education - June 20, 2022 - Prof. Chris Packard, PhD - Glasgow, UK


Show transscript

Video navigation menu

  • Insights from REDUCE-IT and STRENGTH 0:23
  • Overview of potential mechanisms 1:41
  • Focus on lipoprotein synthesis 2:10
  • Focus on plasma lipoproteins 3:12
  • Focus on chronic inflammation 4:37
  • Focus on atherothrombosis 5:56
  • Focus on cell membrane cholesterol 6:46

Educational information

This presentation by Prof. Packard is part of a series titled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".


Prof. Chris Packard, PhD is Honorary Senior Research Fellow at the Institute of Cardiovascular & Medical Sciences at the University of Glasgow, UK.


This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of EPCCS.


Funding for this educational program was provided by an unrestricted educational grant received from Amarin.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: